市場調査レポート
商品コード
1091562

感染症診断の世界市場:製品(試薬、キット、機器、ソフトウェア)、検査タイプ(ラボ、POC)、疾患(COVID-19、インフルエンザ、HAI、HIV、HPV)、技術別(免疫診断薬、NGS、INAAT、PCR)、エンドユーザー(病院、ラボ)別 - 2027年までの予測

Infectious Disease Diagnostics Market by Product (Reagents, Kits, Instrument, Software), Test Type (Lab, POC), Disease (COVID-19, Flu, HAIs, HIV, HPV), Technology (Immunodiagnostics, NGS, INAAT, PCR), End User (Hospitals, Labs) - Global Forecast -2027

出版日: | 発行: MarketsandMarkets | ページ情報: 英文 287 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=134.18円
感染症診断の世界市場:製品(試薬、キット、機器、ソフトウェア)、検査タイプ(ラボ、POC)、疾患(COVID-19、インフルエンザ、HAI、HIV、HPV)、技術別(免疫診断薬、NGS、INAAT、PCR)、エンドユーザー(病院、ラボ)別 - 2027年までの予測
出版日: 2022年06月11日
発行: MarketsandMarkets
ページ情報: 英文 287 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界の感染症診断の市場規模は、2022年の355億米ドルから、-1.4%のCAGRで推移し、2027年までに331億米ドルとなる見通しです。

同市場は、感染症の兆候、POC検査の増加傾向、技術的進歩などの要因で牽引されています。しかし、不利な償還条件により、今後数年間の市場成長の抑制が予想されます。

当レポートでは、世界の感染症診断市場について調査し、市場力学、セグメント・地域別の市場分析、競合情勢、主要企業のプロファイルなどの情報を提供しています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • 市場力学
    • 促進要因
    • 抑制要因
    • 市場機会
    • 課題
    • COVID-19の影響
  • 価格分析
  • 特許分析
  • バリューチェーン分析
  • サプライチェーン分析
  • エコシステム市場マップ
  • ポーターのファイブフォース分析
  • PESTLE分析
  • 規制状況
  • 貿易分析
  • 技術分析
  • 2022年から2023年の主な会議とイベント
  • 顧客のビジネスに影響を与える動向/ディスラプション
  • 主な利害関係者と購入基準
  • ケーススタディ

第6章 感染症診断市場:製品・サービス別

  • 試薬・キット・消耗品
  • 機器
  • ソフトウェア・サービス

第7章 感染症診断市場:検査タイプ別

  • ラボ
  • POC

第8章 感染症診断市場:技術別

  • 主な注意事項
  • イムノダイアグノスティックス
  • PCR
  • 臨床微生物学
  • INAAT
  • DNAシーケンシング・NGS
  • DNAマイクロアレイ
  • その他

第9章 感染症診断市場:疾患タイプ別

  • COVID-19
  • 肝炎
  • HIV
  • 院内感染
  • 蚊媒介性疾患
  • HPV
  • クラミジア・トラコマチス
  • ナイセリア淋菌
  • 結核
  • インフルエンザ
  • 梅毒
  • その他

第10章 感染症診断市場:エンドユーザー別

  • 診断ラボ
  • 病院・クリニック
  • 学術研究
  • その他

第11章 感染症診断市場:地域別

  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • その他
  • ラテンアメリカ
  • 中東・アフリカ

第12章 競合情勢

  • 概要
  • 主要企業の戦略/有力企業
  • 主要市場参入企業の収益シェア分析
  • 市場シェア分析
  • 企業評価クアドラント
  • スタートアップ/中小企業の競合リーダーシップマッピング(2021年)
  • 競合ベンチマーキング
  • 競合シナリオ

第13章 企業プロファイル

  • 主要企業
    • ABBOTT LABORATORIES
    • F. HOFFMANN-LA ROCHE LTD.
    • THERMO FISHER SCIENTIFIC INC.
    • SIEMENS HEALTHINEERS AG
    • BIOMERIEUX SA
    • DANAHER CORPORATION
    • HOLOGIC, INC.
    • BECTON, DICKINSON AND COMPANY
    • PERKINELMER, INC.
    • SEEGENE, INC.
    • QUIDEL CORPORATION
    • QIAGEN N.V.
    • DIASORIN S.P.A
    • BIO-RAD LABORATORIES, INC.
    • GRIFOLS S.A.
    • ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC
    • SYSMEX CORPORATION
  • その他の企業
    • MERIDIAN BIOSCIENCE
    • ORASURE TECHNOLOGIES
    • CO-DIAGNOSTICS
    • CHEMBIO DIAGNOSTIC SYSTEMS
    • TRINITY BIOTECH PLC
    • GENETIC SIGNATURES LTD.
    • EPITOPE DIAGNOSTICS
    • TRIVITRON HEALTHCARE
    • ELITECHGROUP
    • MERIL LIFESCIENCES PVT. LTD.
    • INBIOS INTERNATIONAL
    • UNIOGEN OY
    • VELA DIAGNOSTICS

第14章 付録

目次
Product Code: MD 3088

The global infectious disease diagnostics market size is projected to reach USD 33.1 billion by 2027 from USD 35.5 billion in 2022, at a -1.4% CAGR.Market is driven by factors such as indication of infectious diseases, growing trend in POC testing and rising technological advancements. However,an unfavorable reimbursement scenario is expected to limit market growth to a certain extent in the forecasted years.

"The reagents, kits, and consumablesaccounted for the largest market sharein theinfectious disease diagnostics market, byproduct& service, during the forecast period"

The infectious disease diagnostics market is segmented into reagents, kits, and consumables; instruments; and software & services. The reagents, kits, and consumables segment accounted for the largest market share in the infectious disease diagnostics market in 2021. Major factors driving the growth of this segment include the increasing number of infectious disease diagnostic tests carried out, the growing need for more reliable, more specific, and faster detection of infectious diseases in the early stages. This is the largest and fastest-growing product segment in the infectious disease diagnostics market. Also, the frequent need for reagents & kits makes it a recurrent cost.

"Mosquito-borne diseasessegment accounted for the highest CAGR"

Based on the disease type, the infectious disease diagnostics market is segmented into COVID-19, HIV, Hospital-acquired infections, hepatitis, Chlamydia trachomatis, Neisseria Gonorrhea, HPV, Tuberculosis, influenza, syphilis, mosquito-borne diseases and other infectious diseases. In 2021, the mosquito-borne diseasessegment accounted for the highest CAGR.

"Diagnostic Laboratoriessegment accounted for the largest market share"

Based on end-users, the infectious disease diagnostics market is segmented into diagnostic laboratories, hospitals & clinics, academic research institutes, and other end users. The diagnostic laboratories segment accounted for the largest market share in 2021. This can be attributed to the development of complex and highly specialized tests in infectious disease diagnostics and strengthening healthcare infrastructures for efficient disease diagnosis and treatment.

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type: Tier 1 - 40%, Tier 2 - 30%,and Tier 3 -30%
  • By Designation: C-level - 27%, D-level - 18%, and Others - 55%
  • By Region: North America -51%, Europe - 21%, Asia Pacific - 18%, Latin America - 6%, and the Middle East & Africa - 4%

Lits of Companies Profiled in the Report:

  • Abbott Laboratories (US)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • bioMerieux SA (France)
  • Thermo Fisher Scientific Inc. (US)
  • Danaher Corporation (US)
  • QuidelCorporation(US)
  • Hologic, Inc. (US)
  • PerkinElmer Inc. (US)
  • Bio-Rad Laboratories, Inc. (US)
  • QIAGEN (Netherlands)
  • Siemens Healthineers AG (Germany)
  • Becton, Dickinson and Company (US)
  • DiaSorin S.p.A (Italy)
  • Grifols S.A. (Spain)
  • Sysmex Corporation (Japan)
  • Seegene Inc. (South Korea)
  • Ortho Clinical Diagnostics (US)
  • Genetic Signatures (Australia)
  • Meridian Bioscience (US)
  • OraSure Technologies (US)
  • Trinity Biotech Plc. (Ireland)
  • Chembio Diagnostic Systems (US)
  • Co-Diagnostics (US)
  • ELITechGroup (France)
  • Epitope Diagnostics (US)
  • Trivitron Healthcare (India)
  • Meril Life Sciences Pvt. Ltd. (India)
  • InBios International (US)
  • Uniogen Oy (Finland)
  • Vela Diagnostics (Singapore)

Research Coverage:

This report provides a detailed picture of the global infectious disease diagnostics market. It aims at estimating the size and future growth potential of the market across different segments, such as product& service, test of testing, technology,disease type, end user, and region. The report also includes an in-depth competitive analysis ofthe key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall infectious disease diagnostics market and its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, challenges, and opportunities.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS
  • 1.3 MARKETS SCOPE
    • 1.3.1 MARKETS COVERED
    • FIGURE 1 INFECTIOUS DISEASE DIAGNOSTICS MARKET SEGMENTATION
    • FIGURE 2 MARKETS COVERED - BY REGION
    • 1.3.2 INFECTIOUS DISEASE DIAGNOSTICS MARKET: YEARS CONSIDERED
    • FIGURE 3 YEARS CONSIDERED
  • 1.4 CURRENCY
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS
  • 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
  • 2.2 RESEARCH APPROACH
    • FIGURE 4 INFECTIOUS DISEASE DIAGNOSTICS MARKET: RESEARCH DESIGN METHODOLOGY
    • 2.2.1 SECONDARY DATA
      • 2.2.1.1 Key data from secondary sources
      • 2.2.1.2 Secondary research activities
    • 2.2.2 PRIMARY DATA
      • 2.2.2.1 Primary sources
      • 2.2.2.2 Key data from primary sources
      • 2.2.2.3 Key industry insights
      • 2.2.2.4 Breakdown of primary interviews
    • FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE AND DEMAND SIDE PARTICIPANTS
    • FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • 2.3 MARKET SIZE ESTIMATION
    • 2.3.1 BOTTOM-UP APPROACH
      • 2.3.1.1 Approach 1: Company revenue estimation approach
    • FIGURE 7 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
      • 2.3.1.2 Approach 2: Presentations of companies and primary interviews
      • 2.3.1.3 Growth forecast
      • 2.3.1.4 CAGR projections
    • FIGURE 8 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS
    • 2.3.2 TOP-DOWN APPROACH
    • FIGURE 9 INFECTIOUS DISEASE DIAGNOSTICS MARKET: TOP-DOWN APPROACH
  • 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 10 DATA TRIANGULATION METHODOLOGY
  • 2.5 MARKET SHARE
  • 2.6 STUDY ASSUMPTIONS
  • 2.7 LIMITATIONS
  • 2.8 GROWTH RATE ASSUMPTIONS
  • 2.9 RISK ASSESSMENT
    • 2.9.1 RISK ASSESSMENT: INFECTIOUS DISEASE DIAGNOSTICS MARKET

3 EXECUTIVE SUMMARY

    • FIGURE 11 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022 VS. 2027 (USD MILLION)
    • FIGURE 12 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)
    • FIGURE 13 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022 VS. 2027 (USD MILLION)
    • FIGURE 14 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
    • FIGURE 15 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION, 2022 VS. 2027 (USD MILLION)

4 PREMIUM INSIGHTS

  • 4.1 INFECTIOUS DISEASE DIAGNOSTICS MARKET OVERVIEW
    • FIGURE 16 RISING ADOPTION OF POC DIAGNOSTICS TO SUPPORT MARKET GROWTH DURING FORECAST PERIOD
  • 4.2 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022 VS. 2027 (USD MILLION)
    • FIGURE 17 REAGENTS, KITS, AND CONSUMABLES SEGMENT TO COMMAND LARGEST MARKET SHARE BY PRODUCT & SERVICE IN 2022
  • 4.3 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)
    • FIGURE 18 IMMUNODIAGNOSTICS TO DOMINATE MARKET DURING FORECAST PERIOD
  • 4.4 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2022 VS. 2027
    • FIGURE 19 DIAGNOSTIC LABORATORIES TO DOMINATE END USER MARKET

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 20 INFECTIOUS DISEASE DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Global prevalence of infectious diseases
      • 5.2.1.2 Rising focus on R&D and funding in infectious disease diagnostics
      • 5.2.1.3 Growing awareness for early disease diagnosis in developing countries
      • 5.2.1.4 Rising technological advancements in infectious disease diagnostics
      • 5.2.1.5 Shift in focus from centralized laboratories to decentralized POC testing
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Unfavorable reimbursement scenario
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Growth opportunities in growing economies
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Changing regulatory landscape
      • 5.2.4.2 Operational barriers
    • 5.2.5 IMPACT OF COVID-19 ON INFECTIOUS DISEASE DIAGNOSTICS MARKET
  • 5.3 PRICING ANALYSIS
    • 5.3.1 INDICATIVE PRICING MODEL ANALYSIS
    • TABLE 1 INDICATIVE PRICE OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS (2022)
  • 5.4 PATENT ANALYSIS
    • FIGURE 21 LIST OF MAJOR PATENTS FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGIES
    • 5.4.1 LIST OF MAJOR PATENTS
  • 5.5 VALUE CHAIN ANALYSIS
    • FIGURE 22 VALUE CHAIN ANALYSIS: MAJOR VALUE IS ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
  • 5.6 SUPPLY CHAIN ANALYSIS
    • FIGURE 23 INFECTIOUS DISEASE DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS
  • 5.7 ECOSYSTEM MARKET MAP
    • FIGURE 24 INFECTIOUS DISEASE DIAGNOSTICS MARKET: ECOSYSTEM MARKET MAP
    • 5.7.1 INFECTIOUS DISEASE DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM
  • 5.8 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 2 INFECTIOUS DISEASE DIAGNOSTICS MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.8.1 THREAT FROM NEW ENTRANTS
    • 5.8.2 THREAT FROM SUBSTITUTES
    • 5.8.3 BARGAINING POWER OF BUYERS
    • 5.8.4 BARGAINING POWER OF SUPPLIERS
    • 5.8.5 DEGREE OF COMPETITION
  • 5.9 PESTLE ANALYSIS
  • 5.10 REGULATORY LANDSCAPE
    • 5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 3 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 4 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 5 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 6 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 5.10.2 NORTH AMERICA
      • 5.10.2.1 US
      • 5.10.2.2 Canada
    • 5.10.3 EUROPE
    • TABLE 7 EUROPE: CLASSIFICATION OF DEVICES
    • 5.10.4 ASIA PACIFIC
      • 5.10.4.1 China
      • 5.10.4.2 Japan
      • 5.10.4.3 India
    • 5.10.5 LATIN AMERICA
      • 5.10.5.1 Brazil
      • 5.10.5.2 Mexico
    • 5.10.6 MIDDLE EAST
    • 5.10.7 AFRICA
  • 5.11 TRADE ANALYSIS
    • 5.11.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
    • TABLE 8 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2017-2021 (USD MILLION)
    • TABLE 9 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2017-2021 (USD MILLION)
  • 5.12 TECHNOLOGY ANALYSIS
  • 5.13 KEY CONFERENCES & EVENTS IN 2022-2023
    • TABLE 10 INFECTIOUS DISEASE DIAGNOSTICS MARKET: DETAILED LIST OF CONFERENCES & EVENTS
  • 5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
    • 5.14.1 REVENUE SOURCES TO SHIFT TOWARD TECHNOLOGY-BASED SOLUTIONS DUE TO COVID-19
    • 5.14.2 REVENUE TO SHIFT IN INFECTIOUS DISEASE DIAGNOSTICS MARKET
  • 5.15 KEY STAKEHOLDERS & BUYING CRITERIA
    • 5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 25 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS
    • TABLE 11 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS (%)
    • 5.15.2 BUYING CRITERIA
    • FIGURE 26 KEY BUYING CRITERIA FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS
    • TABLE 12 KEY BUYING CRITERIA FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS
  • 5.16 CASE STUDY
    • FIGURE 27 CASE STUDY: MARKET ASSESSMENT AND CONSUMER BUYING BEHAVIOUR IN INDIA

6 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE

  • 6.1 INTRODUCTION
    • TABLE 13 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 14 PRICES OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS (2021)
  • 6.2 REAGENTS, KITS, AND CONSUMABLES
    • 6.2.1 RECURRENT PURCHASES OF REAGENTS, KITS, AND CONSUMABLES TO PROPEL MARKET GROWTH
    • TABLE 15 INFECTIOUS DISEASE DIAGNOSTIC REAGENTS, KITS, AND CONSUMABLES MARKET, BY REGION, 2020-2027 (USD MILLION)
  • 6.3 INSTRUMENTS
    • 6.3.1 INCREASING NEED FOR FASTER AND MORE ACCURATE TEST RESULTS TO BOOST INSTRUMENTS DEMAND
    • TABLE 16 KEY INSTRUMENTS AVAILABLE IN MARKET
    • TABLE 17 INFECTIOUS DISEASE DIAGNOSTIC INSTRUMENTS MARKET, BY REGION, 2020-2027 (USD MILLION)
  • 6.4 SOFTWARE & SERVICES
    • 6.4.1 GROWING UPTAKE OF ADVANCED INSTRUMENTS TO DRIVE SEGMENT GROWTH
    • TABLE 18 INFECTIOUS DISEASE DIAGNOSTIC SOFTWARE & SERVICES MARKET, BY REGION, 2020-2027 (USD MILLION)

7 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING

  • 7.1 INTRODUCTION
    • TABLE 19 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2020-2027 (USD MILLION)
  • 7.2 LABORATORY TESTING
    • 7.2.1 RISING INCIDENCE OF VARIOUS INFECTIOUS DISEASES TO DRIVE MARKET GROWTH
    • TABLE 20 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR LABORATORY TESTING, BY REGION, 2020-2027 (USD MILLION)
  • 7.3 POC TESTING
    • 7.3.1 INCREASING ADOPTION OF POC TECHNOLOGIES TO DRIVE SEGMENT GROWTH
    • TABLE 21 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POC TESTING, BY REGION, 2020-2027 (USD MILLION)
    • 7.3.2 GLOBAL POC TESTING MARKET, BY END USER
    • TABLE 22 GLOBAL POC TESTING MARKET FOR INFECTIOUS DISEASES, BY END USER, 2020-2027 (USD MILLION)
    • TABLE 23 GLOBAL TESTS ADMINISTERED BY HEALTH PROFESSIONALS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 24 GLOBAL CONSUMER SELF-TESTING MARKET FOR INFECTIOUS DISEASES, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 25 US: POC TESTING MARKET FOR INFECTIOUS DISEASES, BY END USER, 2020-2027 (USD MILLION)
    • 7.3.3 POC TESTING MARKET FOR INFECTIOUS DISEASES BY POINT OF PURCHASE AND POINT OF RESULT
    • TABLE 26 US: POC TESTING MARKET FOR INFECTIOUS DISEASES, BY POINT OF PURCHASE AND POINT OF RESULT, 2020-2027 (USD MILLION)

8 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY

  • 8.1 INTRODUCTION
  • 8.2 PRIMARY NOTES
    • 8.2.1 KEY INDUSTRY INSIGHTS
    • TABLE 27 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
  • 8.3 IMMUNODIAGNOSTICS
    • 8.3.1 RISING PREVALENCE OF INFECTIOUS DISEASES AND DEMAND FOR RAPID DIAGNOSTIC KITS TO DRIVE MARKET GROWTH
    • TABLE 28 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY REGION, 2020-2027 (USD MILLION)
    • 8.3.2 IMMUNODIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY TYPE
    • TABLE 29 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY TYPE, 2020-2027 (USD MILLION)
  • 8.4 PCR
    • 8.4.1 EMERGENCE OF ADVANCED TECHNOLOGIES SUCH AS QRT-PCR TO SUPPORT MARKET GROWTH
    • TABLE 30 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2020-2027 (USD MILLION)
  • 8.5 CLINICAL MICROBIOLOGY
    • 8.5.1 GROWING ADOPTION BY RESEARCHERS AND ACADEMIA TO DRIVE MARKET GROWTH
    • TABLE 31 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CLINICAL MICROBIOLOGY, BY REGION, 2020-2027 (USD MILLION)
  • 8.6 INAAT
    • 8.6.1 COST BENEFITS OF INAAT TO DRIVE MARKET GROWTH
    • TABLE 32 MOLECULAR DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY REGION, 2020-2027 (USD MILLION)
  • 8.7 DNA SEQUENCING & NGS
    • 8.7.1 INCREASING USE OF NGS IN CANCER DIAGNOSIS TO FUEL MARKET GROWTH
    • TABLE 33 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY REGION, 2020-2027 (USD MILLION)
  • 8.8 DNA MICROARRAY
    • 8.8.1 GROWING AWARENESS ABOUT ADVANCED TECHNOLOGIES TO DRIVE MARKET GROWTH
    • TABLE 34 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA MICROARRAY, BY REGION, 2020-2027 (USD MILLION)
  • 8.9 OTHER TECHNOLOGIES
    • TABLE 35 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2020-2027 (USD MILLION)

9 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE

  • 9.1 INTRODUCTION
    • TABLE 36 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
  • 9.2 COVID-19
    • 9.2.1 OUTBREAK OF COVID-19 PANDEMIC TO DOMINATE MARKET SHARE
    • TABLE 37 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR COVID-19, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 38 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR COVID-19, BY REGION, 2020-2027 (MILLION TESTS)
    • TABLE 39 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR COVID-19, BY METHOD, 2020-2027 (USD MILLION)
  • 9.3 HEPATITIS
    • 9.3.1 INCREASING ADOPTION OF ADVANCED TECHNOLOGIES FOR HEPATITIS B DIAGNOSIS TO DRIVE SEGMENT GROWTH
    • TABLE 40 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 41 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY REGION, 2020-2027 (MILLION TESTS)
    • TABLE 42 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY METHOD, 2020-2027 (USD MILLION)
  • 9.4 HIV
    • 9.4.1 HIGH GLOBAL PREVALENCE TO DRIVE SEGMENT GROWTH
    • TABLE 43 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 44 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV, BY REGION, 2020-2027 (MILLION TESTS)
  • 9.5 HOSPITAL-ACQUIRED INFECTIONS
    • 9.5.1 RISING BURDEN OF MRSA INFECTIONS TO DRIVE SEGMENT GROWTH
    • TABLE 45 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HAIS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 46 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HAIS, BY REGION, 2020-2027 (MILLION TESTS)
  • 9.6 MOSQUITO-BORNE DISEASES
    • 9.6.1 INCREASING INCIDENCE OF DENGUE TO DRIVE MARKET GROWTH
    • TABLE 47 MAJOR PRODUCTS: DENGUE TESTING
    • TABLE 48 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR MOSQUITO-BORNE DISEASES, BY REGION, 2020-2027 (USD MILLION)
  • 9.7 HPV
    • 9.7.1 TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET GROWTH
    • TABLE 49 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 50 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV, BY REGION, 2020-2027 (MILLION TESTS)
  • 9.8 CHLAMYDIA TRACHOMATIS
    • 9.8.1 GROWING INCIDENCE OF CHLAMYDIA AND RISING AWARENESS AMONG PATIENTS TO DRIVE MARKET GROWTH
    • TABLE 51 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CT, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 52 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CT, BY REGION, 2020-2027 (MILLION TESTS)
  • 9.9 NEISSERIA GONORRHEA
    • 9.9.1 RISING INCIDENCE OF GONORRHEA AND GROWING FUNDING FOR R&D TO DRIVE MARKET GROWTH
    • TABLE 53 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR NG, BY REGION, 2020-2027 (USD MILLION)
  • 9.10 TUBERCULOSIS
    • 9.10.1 INCREASING BURDEN OF TUBERCULOSIS GLOBALLY TO DRIVE MARKET GROWTH
    • TABLE 54 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 55 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY REGION, 2020-2027 (MILLION TESTS)
    • TABLE 56 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY METHOD, 2020-2027 (USD MILLION)
  • 9.11 INFLUENZA
    • 9.11.1 RISING FOCUS ON CONTROLLING INFLUENZA TO DRIVE MARKET GROWTH
    • TABLE 57 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 58 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY REGION, 2020-2027 (MILLION TESTS)
    • TABLE 59 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY METHOD, 2020-2027 (USD MILLION)
  • 9.12 SYPHILIS
    • 9.12.1 GROWING ADOPTION OF NOVEL TECHNOLOGIES TO SUPPORT MARKET GROWTH
    • TABLE 60 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SYPHILIS, BY REGION, 2020-2027 (USD MILLION)
  • 9.13 OTHER INFECTIOUS DISEASES
    • TABLE 61 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY REGION, 2020-2027 (USD MILLION)

10 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER

  • 10.1 INTRODUCTION
    • TABLE 62 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 10.2 DIAGNOSTIC LABORATORIES
    • 10.2.1 INCREASING OUTSOURCING TO DIAGNOSTIC LABORATORIES FOR REDUCED COSTS TO LED TO LARGEST MARKET SHARE
    • TABLE 63 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2020-2027 (USD MILLION)
  • 10.3 HOSPITALS & CLINICS
    • 10.3.1 INCREASING ADOPTION OF DIAGNOSTIC TOOLS TO SUPPORT MARKET GROWTH
    • TABLE 64 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2020-2027 (USD MILLION)
  • 10.4 ACADEMIC RESEARCH INSTITUTES
    • 10.4.1 FOCUS ON DEVELOPING INNOVATIVE TESTS TO DRIVE MARKET GROWTH
    • TABLE 65 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2020-2027 (USD MILLION)
  • 10.5 OTHER END USERS
    • TABLE 66 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2020-2027 (USD MILLION)

11 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION

  • 11.1 INTRODUCTION
    • TABLE 67 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION, 2020-2027 (USD MILLION)
  • 11.2 NORTH AMERICA
    • FIGURE 28 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SNAPSHOT
    • TABLE 68 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 69 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 70 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 71 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 72 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 11.2.1 US
      • 11.2.1.1 Increasing prevalence of infectious diseases to drive market growth
    • TABLE 73 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 74 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 75 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 76 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 11.2.2 CANADA
      • 11.2.2.1 Focus on affordable tests to drive market growth
    • TABLE 77 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 78 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 79 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 80 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 11.3 EUROPE
    • TABLE 81 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 82 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 83 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 84 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 85 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 11.3.1 GERMANY
      • 11.3.1.1 Increasing healthcare expenditure to drive market growth
    • TABLE 86 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 87 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 88 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 89 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 11.3.2 UK
      • 11.3.2.1 Growing number of accredited diagnostic laboratories to propel market growth
    • TABLE 90 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 91 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 92 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 93 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 11.3.3 FRANCE
      • 11.3.3.1 Rising R&D expenditure and increasing demand for early diagnosis to drive market growth
    • TABLE 94 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 95 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 96 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 97 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 11.3.4 ITALY
      • 11.3.4.1 Adoption of advanced diagnostic technologies to drive market growth
    • TABLE 98 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 99 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 100 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 101 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 11.3.5 SPAIN
      • 11.3.5.1 Rising geriatric population to drive market growth
    • TABLE 102 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 103 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 104 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 105 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 11.3.6 REST OF EUROPE
    • TABLE 106 REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 107 REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 108 REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 109 REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 11.4 ASIA PACIFIC
    • FIGURE 29 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET SNAPSHOT
    • TABLE 110 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 111 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 112 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 113 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 114 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 11.4.1 CHINA
      • 11.4.1.1 Growing public access to modern healthcare to drive market growth
    • TABLE 115 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 116 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 117 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 118 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 11.4.2 JAPAN
      • 11.4.2.1 Universal healthcare reimbursement policy to drive market growth
    • TABLE 119 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 120 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 121 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 122 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 11.4.3 INDIA
      • 11.4.3.1 Increasing private & public investments in healthcare system to drive market growth
    • TABLE 123 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 124 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 125 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 126 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 11.4.4 REST OF ASIA PACIFIC
    • TABLE 127 REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 128 REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 129 REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 130 REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 11.5 LATIN AMERICA
    • 11.5.1 RISING DISEASE PREVALENCE AND HEALTHCARE EXPENDITURE TO DRAW FOREIGN PLAYERS
    • TABLE 131 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 132 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 133 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 134 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 11.6 MIDDLE EAST & AFRICA
    • 11.6.1 RISING ACCESS TO ADVANCED TECHNOLOGIES AND GROWING INVESTMENTS TO SUPPORT MARKET GROWTH
    • TABLE 135 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 136 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 137 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 138 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020-2027 (USD MILLION)

12 COMPETITIVE LANDSCAPE

  • 12.1 OVERVIEW
  • 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • 12.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS
    • TABLE 139 OVERVIEW OF STRATEGIES DEPLOYED BY KEY INFECTIOUS DISEASE DIAGNOSTIC MANUFACTURING COMPANIES
  • 12.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
    • FIGURE 30 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN INFECTIOUS DISEASE DIAGNOSTICS MARKET
  • 12.4 MARKET SHARE ANALYSIS
    • 12.4.1 INFECTIOUS DISEASE DIAGNOSTICS MARKET
    • FIGURE 31 INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER (2021)
    • TABLE 140 INFECTIOUS DISEASE DIAGNOSTICS MARKET: DEGREE OF COMPETITION
  • 12.5 COMPANY EVALUATION QUADRANT
    • 12.5.1 LIST OF EVALUATED VENDORS
    • 12.5.2 STARS
    • 12.5.3 EMERGING LEADERS
    • 12.5.4 PERVASIVE PLAYERS
    • 12.5.5 PARTICIPANTS
    • FIGURE 32 INFECTIOUS DISEASE DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING, 2021
  • 12.6 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/ SMES (2021)
    • 12.6.1 PROGRESSIVE COMPANIES
    • 12.6.2 STARTING BLOCKS
    • 12.6.3 RESPONSIVE COMPANIES
    • 12.6.4 DYNAMIC COMPANIES
    • FIGURE 33 INFECTIOUS DISEASE DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES, 2021
  • 12.7 COMPETITIVE BENCHMARKING
    • 12.7.1 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS
    • FIGURE 34 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF TOP PLAYERS IN INFECTIOUS DISEASE DIAGNOSTICS MARKET
    • TABLE 141 INFECTIOUS DISEASE DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS
    • TABLE 142 COMPANY PRODUCT & SERVICE FOOTPRINT
    • TABLE 143 COMPANY REGIONAL FOOTPRINT
    • TABLE 144 INFECTIOUS DISEASE DIAGNOSTICS MARKET: DETAILED LIST OF KEY START-UPS/SMES
  • 12.8 COMPETITIVE SCENARIO
    • 12.8.1 PRODUCT LAUNCHES
    • TABLE 145 KEY PRODUCT LAUNCHES & REGULATORY APPROVALS
    • 12.8.2 DEALS
    • TABLE 146 KEY DEALS

13 COMPANY PROFILES

  • (Business overview, Products offered, Recent Developments, MNM view)**
  • 13.1 KEY PLAYERS
    • 13.1.1 ABBOTT LABORATORIES
    • TABLE 147 ABBOTT LABORATORIES: BUSINESS OVERVIEW
    • FIGURE 35 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021)
    • TABLE 148 PRODUCT LAUNCHES & APPROVALS
    • 13.1.2 F. HOFFMANN-LA ROCHE LTD.
    • TABLE 149 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW
    • FIGURE 36 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2021)
    • 13.1.3 THERMO FISHER SCIENTIFIC INC.
    • TABLE 150 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
    • FIGURE 37 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2021)
    • 13.1.4 SIEMENS HEALTHINEERS AG
    • TABLE 151 SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW
    • FIGURE 38 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2021)
    • 13.1.5 BIOMERIEUX SA
    • TABLE 152 BIOMERIEUX SA: BUSINESS OVERVIEW
    • FIGURE 39 BIOMERIEUX SA: COMPANY SNAPSHOT (2021)
    • 13.1.6 DANAHER CORPORATION
    • TABLE 153 DANAHER CORPORATION: BUSINESS OVERVIEW
    • FIGURE 40 DANAHER CORPORATION: COMPANY SNAPSHOT (2021)
    • 13.1.7 HOLOGIC, INC.
    • TABLE 154 HOLOGIC, INC.: BUSINESS OVERVIEW
    • FIGURE 41 HOLOGIC, INC.: COMPANY SNAPSHOT (2021)
    • 13.1.8 BECTON, DICKINSON AND COMPANY
    • TABLE 155 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
    • FIGURE 42 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2021)
    • 13.1.9 PERKINELMER, INC.
    • TABLE 156 PERKINELMER, INC.: BUSINESS OVERVIEW
    • FIGURE 43 PERKINELMER, INC.: COMPANY SNAPSHOT (2021)
    • 13.1.10 SEEGENE, INC.
    • TABLE 157 SEEGENE, INC.: BUSINESS OVERVIEW
    • FIGURE 44 SEEGENE, INC.: COMPANY SNAPSHOT (2021)
    • 13.1.11 QUIDEL CORPORATION
    • TABLE 158 QUIDEL CORPORATION: BUSINESS OVERVIEW
    • FIGURE 45 QUIDEL CORPORATION: COMPANY SNAPSHOT (2021)
    • 13.1.12 QIAGEN N.V.
    • TABLE 159 QIAGEN N.V.: BUSINESS OVERVIEW
    • FIGURE 46 QIAGEN N.V.: COMPANY SNAPSHOT (2021)
    • 13.1.13 DIASORIN S.P.A
    • TABLE 160 DIASORIN S.P.A: BUSINESS OVERVIEW
    • FIGURE 47 DIASORIN S.P.A: COMPANY SNAPSHOT (2021)
    • 13.1.14 BIO-RAD LABORATORIES, INC.
    • TABLE 161 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
    • FIGURE 48 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2021)
    • 13.1.15 GRIFOLS S.A.
    • TABLE 162 GRIFOLS S.A.: BUSINESS OVERVIEW
    • FIGURE 49 GRIFOLS S.A.: COMPANY SNAPSHOT (2021)
    • 13.1.16 ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC
    • TABLE 163 ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC: BUSINESS OVERVIEW
    • FIGURE 50 ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC: COMPANY SNAPSHOT (2021)
    • 13.1.17 SYSMEX CORPORATION
    • TABLE 164 SYSMEX CORPORATION: BUSINESS OVERVIEW
    • FIGURE 51 SYSMEX CORPORATION: COMPANY SNAPSHOT (2021)
  • 13.2 OTHER PLAYERS
    • 13.2.1 MERIDIAN BIOSCIENCE
    • 13.2.2 ORASURE TECHNOLOGIES
    • 13.2.3 CO-DIAGNOSTICS
    • 13.2.4 CHEMBIO DIAGNOSTIC SYSTEMS
    • 13.2.5 TRINITY BIOTECH PLC
    • 13.2.6 GENETIC SIGNATURES LTD.
    • 13.2.7 EPITOPE DIAGNOSTICS
    • 13.2.8 TRIVITRON HEALTHCARE
    • 13.2.9 ELITECHGROUP
    • 13.2.10 MERIL LIFESCIENCES PVT. LTD.
    • 13.2.11 INBIOS INTERNATIONAL
    • 13.2.12 UNIOGEN OY
    • 13.2.13 VELA DIAGNOSTICS
  • *Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.

14 APPENDIX

  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 14.3 AVAILABLE CUSTOMIZATIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS